Sugi Predict

Sugi Predict / Compounds / SCHEMBL409105

SCHEMBL409105

SCHEMBL409105

COC(=O)CN(CC(=O)O)C(=O)CNC(=O)CNC(=O)OC(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA14 Q9ULX7 1/20 0.37
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ GAA P10253 1/20 0.35
▸ RECQL P46063 1/20 0.34
▸ NPFFR1 Q9GZQ6 1/20 0.33
▸ NPFFR2 Q9Y5X5 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ MAOA P21397 1/20 0.33
▸ MAOB P27338 1/20 0.33
▸ SIGMAR1 Q99720 1/20 0.32
▸ CTSL P07711 1/20 0.32
▸ CTSB P07858 1/20 0.32
▸ CTSS P25774 1/20 0.32
▸ EPHX2 P34913 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL409603 0.95 CA12 (0.40) CA12CA2CA14MEN1KMT2A
SCHEMBL31041082 0.93 MEN1 (0.39) CA12CA2CA14MEN1KMT2A
SCHEMBL18249515 0.90 ALDH1A1 (0.39) MEN1KMT2AGAANPFFR1NPFFR2
SCHEMBL19579307 0.88 CA12 (0.36) CA12CA2CA14MEN1KMT2A
SCHEMBL10046300 0.88 CA12 (0.36) CA12CA2CA14MEN1KMT2A
SCHEMBL19204194 0.88 CA12 (0.36) CA12CA2CA14MEN1KMT2A
SCHEMBL15712078 0.87 CA12 (0.35) CA12CA2CA14MEN1KMT2A
SCHEMBL10046503 0.87 CA12 (0.35) CA12CA2CA14MEN1KMT2A
SCHEMBL15712065 0.87 CA12 (0.35) CA12CA2CA14MEN1KMT2A
SCHEMBL19446137 0.86 CA12 (0.36) CA12CA2CA14MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210274789-A1 Antimicrobial Surface Treatment KODE BIOTECH LTD (NZ) 2021-09-09 — — US disclosed
EP-3221337-B1 MULTIVALENT LIGAND-LIPID CONSTRUCTS BOVIN NICOLAI VLADIMIROVICH (RU) 2021-08-04 — — EP disclosed
EP-3221337-B1 MULTIVALENT LIGAND-LIPID CONSTRUCTS BOVIN NICOLAI VLADIMIROVICH (RU) 2021-08-04 — — EP disclosed
US-20210139540-A1 MULTIVALENT LIGAND-LIPID CONSTRUCTS BOVIN NICOLAI VLADIMIROVICH (RU) 2021-05-13 — — US disclosed
US-20210139540-A1 MULTIVALENT LIGAND-LIPID CONSTRUCTS BOVIN NICOLAI VLADIMIROVICH (RU) 2021-05-13 — — US disclosed
US-10919941-B2 Functional lipid constructs KODE BIOTECH LIMITED (NZ) 2021-02-16 — — US disclosed
US-10919941-B2 Functional lipid constructs KODE BIOTECH LIMITED (NZ) 2021-02-16 — — US disclosed
US-10781235-B2 Multivalent ligand-lipid constructs BOVIN NICOLAI VLADIMIROVICH (RU) 2020-09-22 — — US disclosed
US-10781235-B2 Multivalent ligand-lipid constructs BOVIN NICOLAI VLADIMIROVICH (RU) 2020-09-22 — — US disclosed
US-20200048309-A1 MULTIVALENT LIGAND-LIPID CONSTRUCTS BOVIN NICOLAI VLADIMIROVICH (RU) 2020-02-13 — — US disclosed
US-20140135477-A1 MULTILIGAND CONSTRUCTS SEMIOTIK LLC (RU) 2014-05-15 — — US disclosed
US-8674061-B2 Multiligand constructs Smiotik LLC (RU) 2014-03-18 — — US disclosed
US-8674061-B2 Multiligand constructs Smiotik LLC (RU) 2014-03-18 — — US disclosed
US-8669084-B2 Functional lipid constructs KODE BIOTECH LIMITED (NZ) 2014-03-11 — — US disclosed
US-8669084-B2 Functional lipid constructs KODE BIOTECH LIMITED (NZ) 2014-03-11 — — US disclosed
US-20120021430-A1 FUNCTIONAL LIPID CONSTRUCTS KODE BIOTECH LIMITED (NZ) 2012-01-26 — — US disclosed
US-20120021430-A1 FUNCTIONAL LIPID CONSTRUCTS KODE BIOTECH LIMITED (NZ) 2012-01-26 — — US disclosed
CN-102282160-A Multi-ligand constructs — 2011-12-14 — — CN disclosed
US-20110257081-A1 MULTIGAND CONSTRUCTS SEMIOTIK LLC (RU) 2011-10-20 — — US disclosed
US-20110257081-A1 MULTIGAND CONSTRUCTS SEMIOTIK LLC (RU) 2011-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048309-A1 MULTIVALENT LIGAND-LIPID CONSTRUCTS PHOSPHO1, MGLL, LPAR6 CA12 2717/4885CA2 4337/4885CA14 2990/4885
US-20210139540-A1 MULTIVALENT LIGAND-LIPID CONSTRUCTS PHOSPHO1, MGLL, LPAR6 CA12 2717/4885CA2 4337/4885CA14 2990/4885
US-10919941-B2 Functional lipid constructs CETP, LCAT, LIPA CA12 224/4885CA2 2207/4885CA14 274/4885
US-20210274789-A1 Antimicrobial Surface Treatment CD68, ARG1, CLTB CA12 3253/4885CA2 3235/4885CA14 3915/4885
US-20110257081-A1 MULTIGAND CONSTRUCTS KLK3, PAICS, BTD CA12 189/4885CA2 3243/4885CA14 138/4885
US-10781235-B2 Multivalent ligand-lipid constructs PHOSPHO1, MGLL, LPAR6 CA12 2717/4885CA2 4337/4885CA14 2990/4885
US-20120021430-A1 FUNCTIONAL LIPID CONSTRUCTS CETP, LCAT, SGMS1 CA12 205/4885CA2 1281/4885CA14 225/4885
US-20140135477-A1 MULTILIGAND CONSTRUCTS KLK3, CD2BP2, PAICS CA12 558/4885CA2 4598/4885CA14 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.